Are growth factors leukemogenic?

Leukemia

Volumn 10, Issue 1, 1996, Pages 175-177

  Brodsky, R A ^a   Bedi, A ^a   Jones, R J ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Apoptosis; Chemotherapy; Growth factors; Secondary leukemia

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GROWTH FACTOR; HEMOPOIETIC GROWTH FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; HEMATOPOIETIC CELL; LEUKEMOGENESIS; PRIORITY JOURNAL;

EID: 0030052946     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Abrams J, Smith M. Acute myeloid leukemia following doxorubicin and cyclophosphamide: increased risk for dose-intensive regimens? Department of Health and Human Services Investigator's Letter. 1994; 1-4.
2. DeCillis A et al. Acute myeloid leukemia (AMD in NSABP B-25 Proc Am Soc Clin Oncol 1995; 14: 98 (abstr.)
3. Pui C et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. New Engl J Med 1991; 325: 1682-1687.
4. Smith MA, Rubinstein L, Ungerleider RD. Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: Estimating the risks. Med Pediat Oncol 1994; 23: 86-98.
5. Greene MH, Young RC, Merrill JM, DeVita VT. Evidence of a treatment dose response in acute nonlymphocytic leukemias which occur after therapy of non-Hodgkin's lymphoma. Cancer Res 1983; 43: 1891-1898.
6. Miller JS et al. Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy. Blood 1994; 83: 3780-3786.
7. Stone RM. Myelodysplastic syndrome after autologous transplantation for lymphoma: the price of progress? Blood 1994; 83. 3437-3440.
8. Traweek ST et al. Clonal karyotypic hematopietic cell abnormalities occurring after autologous bone marrow transplantation for Hodgkin's disease and non-Hodgkin's lymphoma. Blood 1994; 84: 957-963
9. Witherspoon RP et al. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. New Engl J Med 1989; 321: 784-789.
10. Levine EG, Bloomfield CD. Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Semin Oncol 1992; 19: 47-84.
11. Gore SD et al. Impact of in vivo administration of interleukin-3 on proliferation, differentiation, and chemosensitivity of acute myeloid leukemia. Clin Cancer Res 1995, 1: 295-303.
12. Estey E et al. Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF. Blood 1992; 79: 2246-2255.
13. Williams GT et al. Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis. Nature 1990; 343. 76-79
14. Colotta F et al Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. Blood 1992; 80: 2012-2020.
15. Brach MA, deVos S, Gruss H, Herrmann F. Prolongation of survival of human polymorphonuclear neutrophils by granulocyte-macrophage colony-stimulating factor is caused by inhibition of programmed cell death. Blood 1992; 80: 2920-2924
16. Sachs L, Lotem J. Control of programmed cell death in normal and leukemic cells: new implications for therapy. Blood 1993; 82: 15-21.
17. Bedi A. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 1994; 83: 2038-2044.
18. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 1993. 81: 151-157.
19. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-Dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957-967.
20. Collins MKL, Marvel J, Malde P, Lopez-Rivas A. Interleukin 3 protects murine bone marrow cells from apoptosis induced by DNA damaging agents. J Exp Med 1992; 176: 1043-1051.
21. Lotem J, Sachs L. Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor β1 and cancer chemotherapy compounds in myeloid leukemic cells. Blood 1992; 80: 1750-1757.
22. Uckun FM et al. In vivo radioprotective effects of recombinant human granulocyte colony-stimulating factor in lethally irradiated mice. Blood 1990; 75: 638-645.
23. Williams GT. Programmed cell death: apoptosis and oncogenesis. Cell 1991; 65: 1097-1098.
24. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988; 335: 440-442.
25. Yin Y et al. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 1992; 70: 937-948.
26. Bedi A et al. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition following DNA damage: a mechanism of resistance to multiple anticancer agents. Blood 1995; 86: 1148-1158.